Project Grant HT94252510841
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14611, USA
Similar Awards
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $660,772 to the University of Rochester to conduct research on "Anticodon-Edited (ACE) tRNA Treatment of Nonsense-Mediated Duchenne Muscular Dystrophy". The award period runs from August 1, 2025 to July 31, 2029. The University of Rochester, a leading private research institution, will leverage its expertise in medicine, neuroscience, and advanced...
The University of Rochester was awarded a $1,875,712 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First 3 Years in Children with Duchenne Muscular Dystrophy", will support advanced biomedical research to investigate medical solutions for Duchenne muscular dystrophy, a rare genetic disorder. The grant has a...
This federal Project Grant award of $513,653.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by the University of Arkansas to develop self-delivering gene editors for the correction of Duchenne muscular dystrophy. The award period runs from August 15, 2024 to August 14, 2026, and aligns with the program's goal of transforming healthcare for military service members and the broader public through innovative...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
This federal Project Grant award of $345,664.00 from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, supports an advanced biomedical research initiative led by Royal Holloway University of London. The research project aims to develop an AAV-based microdystrophin gene therapy for Duchenne muscular dystrophy, with a focus on enhancing immune protection through capsid bioengineering. The award period spans from December 1, 2024 to November 30,...
This federal Project Grant award of $551,216.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research aimed at elucidating the functional role of the PPP1R1B-lncRNA in myocyte repair for Duchenne muscular dystrophy. The award, with a performance period from August 1, 2025 to July 31, 2027, will be executed by the University of California, Los Angeles (UCLA) to conduct this critical research...
This $539,400 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports vascular targeted therapy research for Duchenne muscular dystrophy. The grant was awarded to the Regents of the University of Minnesota, a major land-grant research university, to conduct this cutting-edge biomedical research project. The research aims to develop new treatments and advance scientific understanding of this neurological disorder, which...
The federal Project Grant award ID HT94252510342, totaling $405,341.00, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The award supports the use of proresolution and restorative pharmacology approaches for Duchenne muscular dystrophy (DMD) therapy at the Children's Research Institute, a non-profit pediatric research organization in Washington, D.C. The award will fund advanced biomedical research and development focused...
The U.S. Department of Defense's Defense Health Agency has awarded a $1,179,730 Project Grant to The Research Foundation for the State University of New York (RF-SUNY) at the University at Albany. The grant, under the Military Medical Research and Development program (CFDA 12.420), will fund research to identify new biological and therapeutic targets for myotonic dystrophy type 1, a genetic disorder affecting muscle function. The four-year grant, which began on April 1, 2024, will support basic,...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,938,711 Project Grant to The Research Foundation for the State University of New York (RF-SUNY) on April 1, 2024. The grant will fund research to identify new biological and therapeutic targets for myotonic dystrophy type 1, a genetic disorder that causes progressive muscle weakness and wasting. The project aims to transform health care for service members and the public by conducting...